The latest trading session saw Johnson & Johnson (JNJ) ending at $149.43, denoting a +1.62% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily gain of 1.02%. Elsewhere, the Dow saw an upswing of 1.09%, while the tech-heavy Nasdaq appreciated by 1.18%. Prior to today's trading, shares of the world's biggest maker of health care products had gained 0.2% over the past month. This has outpaced the Medical sector's loss of 1.82% and lagged the S&P 500's gain of 4.44% in that time. Market participants will be closely following the financial results of Johnson & Johnson in its upcoming release. The company plans to announce its earnings on July 17, 2024. In that report, analysts expect Johnson & Johnson to post earnings of $2.73 per share. This would mark a year-over-year decline of 2.5%. Meanwhile, our latest consensus estimate is calling for revenue of $22.38 billion, down 12.32% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $10.62 per share and revenue of $88.38 billion, indicating changes of +7.06% and -4.99%, respectively, compared to the previous year. Investors should also note any recent changes to analyst estimates for Johnson & Johnson. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.09% lower within the past month. As of now, Johnson & Johnson holds a Zacks Rank of #3 (Hold). Digging into valuation, Johnson & Johnson currently has a Forward P/E ratio of 13.84. This represents a discount compared to its industry's average Forward P/E of 14.74. It's also important to note that JNJ currently trades at a PEG ratio of 2.45. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.86 at the close of the market yesterday. The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 101, putting it in the top 41% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...